AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?

Buchan, AM; Lesiuk, H; Barnes, KA; Li, H; Huang, ZG; Smith, KE; Xue, D

Abstract:

The cytoprotective effects of MK-801 and NBQX, selective N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists, respectively, were compared both singularly and in combination in models of transient severe forebrain and transient focal cerebral ischemia. After 10 minutes of four-vessel occlusion ischemia, the sodium salt of NBQX (30 mg/kg IP) given at the time of reperfusion and, subsequently, 15 and 30 minutes later produced a dr...

Expand abstract

Publication status:

Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Buchan, A. M., Lesiuk, H., Barnes, K. A., Li, H., Huang, Z. G., Smith, K. E., & Xue, D. (1993). AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke; a Journal of Cerebral Circulation, 24(12 Suppl), I148–I152.

MLA Style

Buchan, A. M., et al. “AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials than NMDA Antagonists?” Stroke; a Journal of Cerebral Circulation, vol. 24, no. 12 Suppl, 1993, pp. I148–I152.

Chicago Style

Buchan, AM, H Lesiuk, KA Barnes, H Li, ZG Huang, KE Smith, and D Xue. 1993. “AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials than NMDA Antagonists?” Stroke; a Journal of Cerebral Circulation 24 (12 Suppl): I148–I152.
Tweet
Print